Catalio Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Catalio Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.47M	Sell	31,759 -97,352	-75%	-$22.7M	1.59%	24
2026 Q1	$29.5M	Buy	129,111 +9,846	+8%	+$2.21M	6.17%	3
2025 Q4	$25.4M	Sell	119,265 -25,689	-18%	-$5.31M	4.5%	7
2025 Q3	$28.8M	Sell	144,954 -34,972	-19%	-$6.52M	5.33%	5
2025 Q2	$31.1M	Sell	179,926 -15,597	-8%	-$2.54M	6.51%	4
2025 Q1	$30.5M	Sell	195,523 -20,064	-9%	-$2.87M	7.41%	5
2024 Q4	$29.7M	Buy	+215,587	New	+$28.3M	6.49%	2

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Catalio Capital Management's ASND Position: Q2 2026 in Review

Catalio Capital Management reduced its Ascendis Pharma A/S (ASND) stake by 75% in Q2 2026, selling an estimated $22.7M and leaving 31,759 shares worth $8.47M. The position accounts for 1.59% of the portfolio, ranked #24.

Catalio Capital Management first reported a position in ASND in Q4 2024 and has held it in 7 quarters since. The position peaked at $31.1M in Q2 2025. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Catalio Capital Management held 31,759 shares of Ascendis Pharma A/S worth $8.47M as of Q2 2026.
Catalio Capital Management sold 97,352 Ascendis Pharma A/S shares in Q2 2026, an estimated $22.7M.
Ascendis Pharma A/S made up 1.59% of Catalio Capital Management's portfolio in Q2 2026, its #24 holding.
Catalio Capital Management first reported a position in Ascendis Pharma A/S in Q4 2024 and has held it in 7 quarters since.
Catalio Capital Management's Ascendis Pharma A/S position peaked at $31.1M in Q2 2025.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Catalio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.